Skip to main content

Table 2 Effects of 3 months of 2-g n-3 PUFA supplementation on clot properties, coagulation parameters and platelet function

From: Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes

Variable

Placebo

n-3 PUFAs

p value

Fibrinogen (g/L)

 Before

2.70 (2.60; 2.95)

2.74 (2.60; 2.97)

0.70

 After

2.73 (2.58; 2.85)

2.72 (2.57; 2.87)

0.91

t50% (min)

 Before

13.14 (±2.77)

13.55 (±3.07)

0.55

 After

12.58 (±2.70)

13.76 (±2.59)

0.07

Lag time (min)

 Before

2.94 (2.52; 3.27)

2.61 (2.33; 3.21)

0.35

 After

2.94 (2.60; 3.28)

2.84 (2.56; 3.17)

0.75

Peak (nM)

 Before

264.54 (220.08; 314.92)

247.05 (211.89; 287.34)

0.27

 After

249.59 (190.94; 336.52)

243.83 (207.82; 293.65)

0.98

tt peak (min)

 Before

5.87 (±0.92)

5.94 (±1.03)

0.76

 After

5.62 (5.00; 6.96)

5.98 (4.96; 6.89)

0.89

F1.2 (pg/mL)

 Before

41.40 (28.80;48.10)

34.70 (26.95; 46.85)

0.56

 After

43.70 (33.90; 49.30)*

37.70 (27.40; 41.55)**

0.04

PR ADP (%)

 Before

57.96 (±14.02)

54.44 (±14.27)

0.36

 After

60.56 (±15.12)

58.19 (±12.52)

0.54

  1. Data shown as number (percentage) for categorical variables and mean (±standard deviation) or median (IQR) for continuous variables
  2. Ks permeation coefficient, t50% clot lysis time, Lag time lag time peak height, ETP endogenous thrombin potential (an area under the thrombin concentration versus the time curve), Peak maximal thrombin concentration, tt peak time do peak, F1.2 prothrombin fragments, PR ADP platelet aggregation 10 µmol/L adenosine diphosphate, PR AA platelet aggregation 5 mmol/L arachidonic acid
  3. * p = 0.05 within the placebo group; ** p = 0.53 within the n-3 PUFA group
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840